company background image
NCNA

NuCana NasdaqGS:NCNA Stock Report

Last Price

US$0.83

Market Cap

US$42.7m

7D

-13.6%

1Y

-67.0%

Updated

01 Dec, 2022

Data

Company Financials +
NCNA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NCNA Stock Overview

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer.

NuCana plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NuCana
Historical stock prices
Current Share PriceUS$0.83
52 Week HighUS$3.32
52 Week LowUS$0.52
Beta1.34
1 Month Change-23.59%
3 Month Change-40.30%
1 Year Change-66.99%
3 Year Change-87.97%
5 Year Change-92.89%
Change since IPO-94.89%

Recent News & Updates

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Nov 30
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22

Recent updates

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Nov 30
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

May 02
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

Jan 17
We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

Sep 30
We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Jun 01
We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

Feb 15
Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Dec 22
How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Shareholder Returns

NCNAUS BiotechsUS Market
7D-13.6%2.7%1.4%
1Y-67.0%-10.3%-16.1%

Return vs Industry: NCNA underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: NCNA underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is NCNA's price volatile compared to industry and market?
NCNA volatility
NCNA Average Weekly Movement12.3%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: NCNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NCNA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199732Hugh Griffithhttps://www.nucana.com

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer.

NuCana plc Fundamentals Summary

How do NuCana's earnings and revenue compare to its market cap?
NCNA fundamental statistics
Market CapUS$42.66m
Earnings (TTM)-US$37.31m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NCNA income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£30.47m
Earnings-UK£30.47m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.59
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NCNA perform over the long term?

See historical performance and comparison